全文获取类型
收费全文 | 1150篇 |
免费 | 34篇 |
国内免费 | 46篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 11篇 |
妇产科学 | 11篇 |
基础医学 | 73篇 |
口腔科学 | 6篇 |
临床医学 | 122篇 |
内科学 | 130篇 |
皮肤病学 | 9篇 |
神经病学 | 138篇 |
特种医学 | 286篇 |
外科学 | 201篇 |
综合类 | 19篇 |
一般理论 | 1篇 |
预防医学 | 80篇 |
眼科学 | 12篇 |
药学 | 29篇 |
肿瘤学 | 98篇 |
出版年
2021年 | 5篇 |
2019年 | 7篇 |
2018年 | 8篇 |
2017年 | 11篇 |
2016年 | 13篇 |
2015年 | 17篇 |
2014年 | 34篇 |
2013年 | 62篇 |
2012年 | 61篇 |
2011年 | 40篇 |
2010年 | 37篇 |
2009年 | 33篇 |
2008年 | 44篇 |
2007年 | 88篇 |
2006年 | 79篇 |
2005年 | 48篇 |
2004年 | 32篇 |
2003年 | 33篇 |
2002年 | 21篇 |
2001年 | 27篇 |
2000年 | 35篇 |
1999年 | 34篇 |
1998年 | 30篇 |
1997年 | 35篇 |
1996年 | 10篇 |
1995年 | 19篇 |
1994年 | 14篇 |
1993年 | 10篇 |
1992年 | 13篇 |
1991年 | 17篇 |
1990年 | 10篇 |
1989年 | 20篇 |
1988年 | 29篇 |
1987年 | 25篇 |
1986年 | 24篇 |
1985年 | 27篇 |
1984年 | 10篇 |
1983年 | 9篇 |
1982年 | 10篇 |
1980年 | 8篇 |
1979年 | 25篇 |
1978年 | 17篇 |
1977年 | 6篇 |
1976年 | 11篇 |
1975年 | 10篇 |
1974年 | 6篇 |
1968年 | 4篇 |
1967年 | 5篇 |
1966年 | 6篇 |
1964年 | 5篇 |
排序方式: 共有1230条查询结果,搜索用时 109 毫秒
991.
Neuropsychologic evaluation requires current test performance be contrasted against a comparison standard to determine if change has occurred. An estimate of premorbid intelligence quotient (IQ) is often used as a comparison standard. The Wechsler Intelligence Scale for Children-Fourth Edition (WISC-IV) is a commonly used intelligence test. However, there is no method to estimate premorbid IQ for the WISC-IV, limiting the test's utility for neuropsychologic assessment. This study develops algorithms to estimate premorbid Full Scale IQ scores. Participants were the American WISC-IV standardization sample (N = 2172). The sample was randomly divided into 2 groups (development and validation). The development group was used to generate 12 algorithms. These algorithms were accurate predictors of WISC-IV Full Scale IQ scores in healthy children and adolescents. These algorithms hold promise as a method to predict premorbid IQ for patients with known or suspected neurologic dysfunction; however, clinical validation is required. 相似文献
992.
Werz MA Schoenberg MR Meador KJ Loring DW Ray PG Kaul-Gupta R Ogrocki P 《Epilepsy & behavior : E&B》2006,8(1):181-191
OBJECTIVE: Outcomes research emphasizes patient self-assessment and preferences in optimizing treatment. We previously showed that lamotrigine produces significantly less cognitive and behavioral impairment compared with topiramate. In the current study we extend these observations to subject self-report of preference for lamotrigine or topiramate independent of potentially confounding effects of seizures or seizure control. Additionally, drug preference was related to effects of lamotrigine and topiramate on objective neuropsychological tests as well as self-perception on behavioral instruments. METHODS: Thirty-seven healthy volunteers completed a double-blind, randomized crossover design incorporating two 12-week treatment periods of lamotrigine and topiramate each titrated to a dose of 300 mg/day. Evaluation of 23 objective neuropsychological and 15 subjective behavioral measures occurred at four times: pretreatment baseline, first treatment, second treatment, and posttreatment baseline. Preference for lamotrigine or topiramate was assessed, while blinding was maintained, at the final study visit when each subject was asked which drug he or she would prefer to take. RESULTS: A large majority (70%) preferred lamotrigine, 16% stated preference for topiramate, and 14% had no preference (drugs equivalent). Consistent with preference, those preferring lamotrigine performed better on 19 of 23 objective and 13 of 15 subjective behavioral measurements while on lamotrigine. Inconsistent with preference, subjects preferring topiramate performed better on 19 of 23 objective and 9 of 15 subjective behavioral measures while on lamotrigine. Topiramate preference also did not correlate with IQ, serum concentration, body mass index, age, or gender. Topiramate preference did relate to responses on the Profile of Mood States. CONCLUSION: Lamotrigine was preferred by the majority of subjects, congruent with objective neuropsychological and subjective behavioral measures. In contrast, for those stating a preference for topiramate the results on objective neuropsychological measures were impaired while fewer complaints were noted on the Profile of Mood States. This suggests that preference for topiramate may be determined by an effect on mood. 相似文献
993.
994.
995.
996.
Leonardo K Bittencourt Ulrike I Attenberger Daniel Lima Ralph Strecker Andre de Oliveira Stefan O Schoenberg Emerson L Gasparetto Daniel Hausmann 《World journal of radiology》2014,6(6):374-380
AIM: To evaluate the impact of computed b = 1400 s/mm2 (C-b1400) vs measured b = 1400 s/mm2 (M-b1400) diffusion-weighted images (DWI) on lesion detection rate, image quality and quality of lesion demarcation using a modern 3T-MR system based on a small-field-of-view sequence (sFOV).METHODS: Thirty patients (PSA: 9.5 ± 8.7 ng/mL; 68 ± 12 years) referred for magnetic resonance imaging (MRI) of the prostate were enrolled in this study. All measurements were performed on a 3T MR system. For DWI, a single-shot EPI diffusion sequence (b = 0, 100, 400, 800 s/mm²) was utilized. C-b1400 was calculated voxelwise from the ADC and diffusion images. Additionally, M-b1400 was acquired for evaluation and comparison. Lesion detection rate and maximum lesion diameters were obtained and compared. Image quality and quality of lesion demarcation were rated according to a 5-point Likert-type scale. Ratios of lesion-to-bladder as well as prostate-to-bladder signal intensity (SI) were calculated to estimate the signal-to-noise-ratio (SNR).RESULTS: Twenty-four lesions were detected on M-b1400 images and compared to C-b1400 images. C-b1400 detected three additional cancer suspicious lesions. Overall image quality was rated significantly better and SI ratios were significantly higher on C-b1400 (2.3 ± 0.8 vs 3.1 ± 1.0, P < 0.001; 5.6 ± 1.8 vs 2.8 ± 0.9, P < 0.001). Comparison of lesion size showed no significant differences between C- and M-b1400 (P = 0.22).CONCLUSION: Combination of a high b-value extrapolation and sFOV may contribute to increase diagnostic accuracy of DWI without an increase of acquisition time, which may be useful to guide targeted prostate biopsies and to improve quality of multiparametric MRI (mMRI) especially under economical aspects in a private practice setting. 相似文献
997.
Nonenhanced ECG‐gated quiescent‐interval single shot MRA: Image quality and stenosis assessment at 3 tesla compared with contrast‐enhanced MRA and digital subtraction angiography
下载免费PDF全文
![点击此处可从《Journal of magnetic resonance imaging : JMRI》网站下载免费的PDF全文](/ch/ext_images/free.gif)
998.
999.
Shane S. Bush Jerry J. Sweet Kevin J. Bianchini Doug Johnson-Greene Pamela M. Dean Mike R. Schoenberg 《The Clinical neuropsychologist》2018,32(3):319-325
Objective: Neuropsychological tests undergo periodic revision intended to improve psychometric properties, normative data, relevance of stimuli, and ease of administration. In addition, new tests are developed to evaluate psychological and neuropsychological constructs, often purporting to improve evaluation effectiveness. However, there is limited professional guidance to neuropsychologists concerning the decision to adopt a revised version of a test and/or replace an older test with a new test purporting to measure the same or overlapping constructs. This paper describes ethical and professional issues related to the selection and use of older versus newer psychological and neuropsychological tests, with the goal of promoting appropriate test selection and evidence-based decision making. Method: Ethical and professional issues were reviewed and considered. Conclusions: The availability of a newer version of a test does not necessarily render obsolete prior versions of the test for purposes that are empirically supported, nor should continued empirically supported use of a prior version of a test be considered unethical practice. Until a revised or new test has published evidence of improved ability to help clinicians to make diagnostic determinations, facilitate treatment, and/or assess change over time, the choice to delay adoption of revised or new tests may be viewed as reasonable and appropriate. Recommendations are offered to facilitate decisions about the adoption of revised and new tests. Ultimately, it is the responsibility of individual neuropsychologists to determine which tests best meet their patients’ needs, and to be able to support their decisions with empirical evidence and sound clinical judgment. 相似文献
1000.